Artificial Intelligence (AI) in Medical Diagnostics Market to Reach USD 3.86 Billion by 2025
|
By LabMedica International staff writers Posted on 16 Apr 2021 |

Illustration
The global Artificial Intelligence (AI) in Medical Diagnostics Market is projected to grow at a CAGR of 50.2% from USD 0.5 billion in 2020 to USD 3.86 billion by 2025, driven primarily by government initiatives to increase the adoption of AI-based technologies, increasing demand for AI tools in the medical field, growing focus on reducing the workload of radiologists, influx of large and complex datasets, growth in funding for AI-based start-ups, and growing number of cross-industry partnerships and collaborations.
Pandemics such as COVID-19 require investments for additional manpower, equipment, consumables, and other resources to ensure 100% preparedness for safety in hospitals and, if needed, eventual treatment of patients. The COVID-19 pandemic is an accelerator for AI technology by creating opportunities for leveraging these tools for healthcare advancement.
These are the latest findings of MarketsandMarkets (Maharashtra, India), a market research and management consulting firm.
On the basis of component, the AI in medical diagnostics market was dominated by the services segment in 2020. However, the software segment is estimated to grow at a higher CAGR during the forecast period, as software solutions help healthcare providers gain a competitive edge despite the challenges of being short-staffed and facing increasing imaging scan volumes.
Based on end user, the AI in medical diagnostics market was dominated by the hospitals segment in 2019 with the largest share of 64.1%. The segment’s large share can be attributed to the rising number of diagnostic imaging procedures performed in hospitals, the growing inclination of hospitals toward the automation and digitization of radiology patient workflow, increasing adoption of minimally invasive procedures in hospitals to improve the quality of patient care, and the rising adoption of advanced imaging modalities to improve workflow efficiency.
Geographically, North America accounted for the largest share of 37.6% of the global AI in medical diagnostics market in 2019. However, the APAC market is projected to register the highest CAGR of 53.2% during the forecast period, primarily due to the growth strategies adopted by companies in the emerging markets, improved medical diagnostic infrastructure, increasing geriatric population, rising prevalence of cancer, and the implementation of favorable government initiatives.
Related Links:
MarketsandMarkets
Pandemics such as COVID-19 require investments for additional manpower, equipment, consumables, and other resources to ensure 100% preparedness for safety in hospitals and, if needed, eventual treatment of patients. The COVID-19 pandemic is an accelerator for AI technology by creating opportunities for leveraging these tools for healthcare advancement.
These are the latest findings of MarketsandMarkets (Maharashtra, India), a market research and management consulting firm.
On the basis of component, the AI in medical diagnostics market was dominated by the services segment in 2020. However, the software segment is estimated to grow at a higher CAGR during the forecast period, as software solutions help healthcare providers gain a competitive edge despite the challenges of being short-staffed and facing increasing imaging scan volumes.
Based on end user, the AI in medical diagnostics market was dominated by the hospitals segment in 2019 with the largest share of 64.1%. The segment’s large share can be attributed to the rising number of diagnostic imaging procedures performed in hospitals, the growing inclination of hospitals toward the automation and digitization of radiology patient workflow, increasing adoption of minimally invasive procedures in hospitals to improve the quality of patient care, and the rising adoption of advanced imaging modalities to improve workflow efficiency.
Geographically, North America accounted for the largest share of 37.6% of the global AI in medical diagnostics market in 2019. However, the APAC market is projected to register the highest CAGR of 53.2% during the forecast period, primarily due to the growth strategies adopted by companies in the emerging markets, improved medical diagnostic infrastructure, increasing geriatric population, rising prevalence of cancer, and the implementation of favorable government initiatives.
Related Links:
MarketsandMarkets
Latest Industry News
- Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business
- Agilent Completes Acquisition of Digital Pathology Platform Developer Proscia
- New Diagnostics Company Onvaro Formed to Expand Decentralized Testing
- Illumina Selected to Support National Genomics Study for Personalized Healthcare in Singapore
- Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk
- CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
- Real Diagnostics Adds Saliva-Based Periodontal Testing With SimplyTest Deal
- Collaboration Brings Tumor-Informed MRD Monitoring to Breast Cancer Care in Abu Dhabi
- Qiagen Agrees to Go Private Through EQT-Led Acquisition
- Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
- Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
- Myriad Genetics to Sell Prenatal Testing Portfolio to Labcorp
- Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch
- Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
- Labcorp Acquisition to Strengthen Specialty Testing and Prostate Cancer Assessment
- Collaboration Advances Genomic Instability Biomarker for Prostate Cancer
Channels
Clinical Chemistry
view channel
Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
Cerebrovascular disease damages blood vessels in the brain and can contribute to tissue injury, microbleeds, white matter damage, stroke, cognitive decline, and dementia. Identifying people at higher risk... Read more
Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL), requires accurate identification to guide further evaluation, monitoring, and treatment. In 2026, an estimated 79,320 people in the U.... Read moreMolecular Diagnostics
view channel
DNA Methylation May Predict Treatment Response in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are disorders in which the bone marrow does not produce healthy blood cells normally. Treatment selection can be challenging because clinicians cannot reliably predict which... Read more
Circulating Tumor DNA Test Identifies Complete Immunotherapy Responders
Immune checkpoint inhibitors have transformed treatment for many metastatic cancers, with some patients achieving durable disease control. However, clinicians remain uncertain about how long therapy should... Read moreHematology
view channel
New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more
Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more
Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways
Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read moreMicrobiology
view channel
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more







